- In February 2025, Thermo Fisher Scientific Inc. announced the acquisition of Solventum's purification and filtration business for USD 4.1 billion. This strategic move is aimed at strengthening Thermo Fisher’s capabilities in bioprocess filtration and sterile processing, significantly expanding its life sciences portfolio. The acquisition is expected to enhance the company’s ability to serve customers in the biologics and vaccine production sectors, reinforcing its leadership in high-performance sterile filtration technologies
- In January 2025, Cytiva, a Danaher Corporation company, launched a next-generation sterile filtration solution engineered for high-concentration biologic feeds. The innovation enables greater throughput with minimal filter area, thereby reducing hold-up volume and product loss. This development addresses a growing need in biopharmaceutical manufacturing for scalable, efficient, and low-waste filtration systems and reflects Cytiva’s continued investment in process intensification
- In April 2025, Amazon Filters Ltd. introduced a suite of high-performance sterile filters and sanitary housings at the InterPhex Conference in New York. These solutions were designed to meet the evolving demands of pharmaceutical and biotech manufacturers, focusing on sterile liquid and gas applications. The company emphasized customizability and operational reliability, reinforcing its commitment to providing tailored sterile filtration technologies to support GMP-compliant production
- In December 2024, Pall Corporation unveiled its new Ultipleat High Flow XT filter cartridges tailored for critical sterile filtration stages in biologics manufacturing. The filters are designed to increase capacity and operational flexibility while maintaining high microbial retention rates. This innovation aligns with the industry’s need for scalable, single-use solutions that reduce contamination risks and support continuous bioprocessing initiatives
- In November 2024, Merck KGaA (MilliporeSigma) announced the expansion of its filtration product line with the launch of the Durapore 0.1 µm sterile membrane filter, designed specifically for ultra-sensitive sterile filtration applications such as virus filtration and endotoxin removal. This development demonstrates Merck’s ongoing efforts to support the rapid growth in cell and gene therapy production by offering ultra-high-performance and regulatory-compliant filtration technologies
